{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sureda A"],"funding":["Takeda Farmacéutica España S.A."],"pagination":["1137"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11987772"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(7)"],"pubmed_abstract":["<h4>Background/objectives</h4>Brentuximab vedotin (BV) has been shown to be effective in the treatment of classical Hodgkin's lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), and CD30-positive cutaneous T-cell lymphoma (CTCL). This study aimed to evaluate the effectiveness and safety of BV retreatment in patients with relapsed/refractory cHL, sALCL, and CD30-positive CTCL.<h4>Methods</h4>This multicenter, non-interventional, retrospective medical chart review study analyzed medical records from 43 patients retreated with BV in Spain. Patients were included if they had relapsed or refractory cHL, sALCL, or CD30-positive CTCL and were previously treated with BV. Demographic characteristics, disease stage, response to treatment, survival outcomes, and adverse events were analyzed.<h4>Results</h4>The study population included 16 patients with cHL, 13 with sALCL, and 14 with CTCL. The majority were male (58.1%) with a mean age of 46.2 years and baseline ECOG scores of 0-1. Among cHL and sALCL patients, disease stage, according to the Ann Arbor classification, ranged from I to IVB, while in CTCL, EORTC clinical stages ranged from IA to IVB. The overall response rate to BV retreatment was 76.7%, with the highest response observed in sALCL (92.3%). Complete remission was achieved in 60.5% of patients. Median progression-free survival was 25.4 months, and overall survival reached 50 months. Treatment failure occurred in 37.2% of patients. BV was generally well tolerated, with peripheral neuropathy being the most frequently reported adverse event.<h4>Conclusions</h4>The BELIEVE study is the largest study to date demonstrating that retreatment with BV is an effective and well-tolerated option for patients with relapsed or refractory CD30-positive malignancies."],"journal":["Cancers"],"pubmed_title":["Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study."],"pmcid":["PMC11987772"],"funding_grant_id":["N/A"],"pubmed_authors":["Aguiar D","Gutierrez A","Sanchez-Gonzalez B","Rodriguez A","Sureda A","Domingo-Domenech E","Infante MS","Lopez-Jimenez J","Giraldo P","Baeza-Montanez L","Capote FJ","Grande M","Garcia-Sanz R","Martinez C","Ortiz-Romero PL"],"additional_accession":[]},"is_claimable":false,"name":"Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study.","description":"<h4>Background/objectives</h4>Brentuximab vedotin (BV) has been shown to be effective in the treatment of classical Hodgkin's lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), and CD30-positive cutaneous T-cell lymphoma (CTCL). This study aimed to evaluate the effectiveness and safety of BV retreatment in patients with relapsed/refractory cHL, sALCL, and CD30-positive CTCL.<h4>Methods</h4>This multicenter, non-interventional, retrospective medical chart review study analyzed medical records from 43 patients retreated with BV in Spain. Patients were included if they had relapsed or refractory cHL, sALCL, or CD30-positive CTCL and were previously treated with BV. Demographic characteristics, disease stage, response to treatment, survival outcomes, and adverse events were analyzed.<h4>Results</h4>The study population included 16 patients with cHL, 13 with sALCL, and 14 with CTCL. The majority were male (58.1%) with a mean age of 46.2 years and baseline ECOG scores of 0-1. Among cHL and sALCL patients, disease stage, according to the Ann Arbor classification, ranged from I to IVB, while in CTCL, EORTC clinical stages ranged from IA to IVB. The overall response rate to BV retreatment was 76.7%, with the highest response observed in sALCL (92.3%). Complete remission was achieved in 60.5% of patients. Median progression-free survival was 25.4 months, and overall survival reached 50 months. Treatment failure occurred in 37.2% of patients. BV was generally well tolerated, with peripheral neuropathy being the most frequently reported adverse event.<h4>Conclusions</h4>The BELIEVE study is the largest study to date demonstrating that retreatment with BV is an effective and well-tolerated option for patients with relapsed or refractory CD30-positive malignancies.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-04-08T19:04:45.359Z","creation":"2025-07-10T03:08:13.317Z"},"accession":"S-EPMC11987772","cross_references":{"pubmed":["40227660"],"doi":["10.3390/cancers17071137"]}}